• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

With an ovarian KRAS combo ready for review, Verastem’s CEO is poised for the transition

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Apr 04, 2024 at 11:22: AM
via Verastem Oncology is now on the precipice of filing for an accelerated approval of a RAS pathway-based combo to treat low-grade serous ovarian cancer, and the transition follows a CEO turnover as Daniel Paterson, who has been with the company “almost since the beginning,” took the helm last year.

article source
 

<



Similar threads

cafead
Imunon Reports Promising Phase 2 Ovarian Cancer Trial ResultsCompany Announcements Imunon Reports Promising Phase 2 Ovarian Cancer Trial Results
Replies
0
Views
14
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
After AbbVie&#039;s ImmunoGen buy, Elahere posts midstage trial win in ovarian cancer subtype
Replies
0
Views
34
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Daiichi Sankyo and Merck dose first subject in ovarian cancer trial
Replies
0
Views
107
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
FDA grants full approval to AbbVie&#039;s ovarian cancer therapy
Replies
0
Views
129
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
PhotonPharma receives FDA clearance for ovarian cancer vaccine trial
Replies
0
Views
40
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote